News

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific ...
Casper, Wyoming Community News Stream.Voting for Oil City’s Best 2025 is NOW OPEN! We’re celebrating all the Stuff Locals Love! VOTE NOW for your favorite Casper-area people, places and things below!
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.52, representing a -5.86% change from its previous close.
Truist Financial analyst Joon Lee maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today. The company’s shares closed yesterday at $27.09. Confident Inv ...
Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.